Canbay A, Kachru N, Haas JS, et al. - In a large, real‐world cohort of German non‐alcoholic fatty liver disease (NAFLD) patients, researchers evaluated how liver disease severity, demographics, and comorbidities influence all‐cause mortality and liver disease progression. The German Institut für angewandte Gesundheitsforschung database was used to source claims data from between 2011 and 2016, which was analyzed retrospectively. Data revealed that the prevalence of NAFLD was 4.7% (n = 215,655) among the 4,580,434 patients in the database. Cardiovascular disease, type 2 diabetes mellitus, hypertension, obesity, and renal impairment were identified as independent mortality predictors. Over 5 years of follow‐up, the cumulative incidence of progression in NAFLD was 10.7%, while in compensated cirrhosis patients, it was 16.7%. Patients with NAFLD had a high risk of mortality that increased with the progression of the disease, which was severely under‐diagnosed. Stopping or reversing fibrosis are needed to prevent progression, which is best accomplished via early identification and effective management.